Researchers of the University of Bristol-led study, published in Science Advances today [23 November], say their findings could lead to the development of a pan-coronavirus treatment to defeat all coronaviruses.
A new study from the Centers for Disease Control and Prevention’s VISION Network presents and analyzes some of the first real-world data on mRNA COVID vaccine effectiveness during Omicron BA.4 and BA.5 predominance for immunocompromised adults.
FAU researchers and collaborators provide the most updated guidance to health care providers and urge how widespread vaccination with these boosters can now avoid the specter of future and more lethal variants becoming a reality.
People with systemic lupus erythematosus, or SLE, who received a “booster” dose of SARS-CoV-2 vaccine after full vaccination are roughly half as likely to have a subsequent “breakthrough” COVID-19 infection, a new study shows.
Mount Sinai-led researchers have shown that tiny, robust immune particles derived from the blood of a llama could provide strong protection against every COVID-19 variant, including Omicron, and 18 similar viruses.
In a letter published in the New England Journal of Medicine, physician-scientists report that the three Omicron subvariants currently dominant in the United States – officially known as subvariants BA.2.12.1, BA.4, and BA.5 – substantially escape neutralizing antibodies induced by both vaccination and previous infection.
The study found that Omicron-specific antibodies reached detectable levels in 86% of nursing home residents and 93% of healthcare workers after receiving the booster shot, compared to just 28% of nursing home residents and healthcare workers after the initial two-dose COVID-19 vaccine series.
Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published June 15 in the Journal of Experimental Medicine (JEM). The antibodies were effective against all SARS-CoV-2 variants of concern tested and could be used alone or in an antibody cocktail to diminish the risk of infection.
The omicron wave of the COVID-19 pandemic in late 2021 and early 2022 spread like a grass fire in America’s densely populated cities but led to higher rates of death in rural counties where vaccinations are lagging.
New research finds vaccinated young adults who were diagnosed with COVID-19 during the “omicron wave” of late 2021 and early 2022 did not have lasting vascular impairment after active infection. The first-of-its-kind study is published ahead of print in the American Journal of Physiology-Heart and Circulatory Physiology.
A recent study jointly conducted by the LKS Faculty of Medicine, The University of Hong Kong (HKUMed) and the Faculty of Medicine, The Chinese University of Hong Kong (CU Medicine) shows that vaccinated individuals can develop more robust and broadly reactive antibody responses against SARS-CoV-2 variants than unvaccinated individuals after an Omicron infection.
A COVID-19 booster shot will provide strong and broad antibody protection against the range of omicron sublineage variants of the SARS-CoV-2 virus in circulation, two new studies using serum from human blood samples suggest.